Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQD3606 in renal insufficiency
NCT06672276Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TQD3606 (4 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak Concentration at 24 hours, Area Under the Concentration-Time Curve at 24 hours and 6 more. Started Nov 2024; status: completed.
02
Drugs
TQD3606
Beyond the preview
Go deeper on NCT06672276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672276.